NEW YORK, March 04, 2023 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following public companies. You can see a copy of the complaints by visiting the links below or you can contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you have suffered damage, you can request that the court appoint you as lead plaintiff. Your ability to participate in a recovery does not require you to serve as lead plaintiff. A lead plaintiff acts on behalf of all other group members in conducting the litigation. The lead plaintiff can select a law firm of his choice. An investor’s ability to participate in a potential future recovery is not contingent on its serving as lead plaintiff.

Y-mAbs Therapeutics, Inc. YMAB
school lesson: October 6, 2020 – October 28, 2022
Meeting: March 20, 2023
For more information: www.bgandg.com/ymab.
The Complaint alleges that during the Class Period, Y-mAbs misrepresented to investors that, according to a series of meetings and other communications between Y-mAbs and the FDA, progress was being made that was consistent with the FDA’s requirement for material evidence to submit efficacy sufficient for approval of omburtamab. What investors were unaware of was that the FDA had repeatedly advised Y-mAbs that the treatment effect of omburtamab cannot be objectively established or quantified based on a comparison between Study 03-133 and an external cohort that provided data from Central German Childhood Cancer Comprises Registry (CGCCR) database due to significant variance in patient populations and lack of tumor response data, and that Study 101 was not sufficiently advanced and demonstrated efficacy to warrant approval. Furthermore, Y-mAbs has not informed investors that it had elected to terminate the March 31, 2022 BLA before…